FDA should reassess postmarket trials for cancer drugs approved via accelerated pathway, researchers say
The FDA may need to reassess how confirmatory trials are conducted after just one-fifth of such trials for cancer drug indications approved via the FDA’s accelerated approval pathway have demonstrated improvements in overall survival (OS), researchers reported Tuesday in JAMA Internal Medicine research.
The researchers looked at 93 cancer drug indications granted accelerated approval by the FDA from 1992 through May 2017, finding confirmatory trials reported that 20% had improvement in overall survival, 21% had improvement in a different surrogate measure and 20% had improvement in the same surrogate measure used in confirmatory trials and preapproval trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.